Suppr超能文献

部分肝切除术与介入治疗对乙型肝炎病毒相关肝细胞癌合并临床显著门静脉高压患者的随机对照临床试验。

Partial hepatectomy versus interventional treatment in patients with hepatitis B virus-related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinical trial.

机构信息

State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.

Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.

出版信息

Cancer Commun (Lond). 2024 Nov;44(11):1337-1349. doi: 10.1002/cac2.12614. Epub 2024 Sep 25.

Abstract

BACKGROUND

The widely accepted view that portal hypertension (PHT) is a contraindication to hepatectomy for patients with hepatocellular carcinoma (HCC) is being increasingly challenged. The long-term survival outcomes and safety of partial hepatectomy versus interventional treatment using ablation with or without pre-ablation transarterial chemoembolization (TACE) in patients with HBV-related HCC within the Milan criteria and with clinically significant PHT were compared in this study.

METHODS

This open-label randomized clinical trial was conducted on consecutive patients with clinically PHT and hepatitis B virus (HBV)-related HCC with tumors which were within the Milan criteria. These patients were randomized 1:1 to receive either partial hepatectomy or interventional treatment between December 2012 and June 2018. The primary endpoint was overall survival (OS); secondary endpoints included recurrence-free survival (RFS) and therapeutic safety.

RESULTS

Each of the 2 groups had 80 patients. The 1-, 3- and 5-year OS rates in the partial hepatectomy group and the interventional treatment group were 95.0%, 86.2%, 69.5% versus 93.8%, 77.5%, 64.9%, respectively (P = 0.325). The corresponding RFS rates were 78.8%, 55.0%, 46.2% versus 71.3%, 52.5%, 45.0%, respectively (P = 0.783). The partial hepatectomy group had a higher complication rate compared to the interventional group (67.5% vs. 20%, P < 0.001). However, the differences were mainly in Clavien-Dindo Grade I complications (P < 0.001), while not significant in Grade II/III/IV/V (All P > 0.05).

CONCLUSIONS

This study shows that partial hepatectomy treatment did not meet prespecified significance for improved OS and RFS compared to interventional treatment for patients with HBV-related HCC within the Milan criteria and with clinically significant PHT. However, partial hepatectomy is still a safe procedure and should be considered as a treatment option rather than a contraindication.

摘要

背景

门静脉高压症(PHT)被广泛认为是肝细胞癌(HCC)患者行肝切除术的禁忌证,但这一观点正受到越来越多的挑战。本研究旨在比较米兰标准范围内、伴有临床显著 PHT 的乙型肝炎病毒(HBV)相关 HCC 患者,行部分肝切除术与消融联合或不联合消融前经肝动脉化疗栓塞术(TACE)的长期生存结局和安全性。

方法

这是一项在连续的、具有临床意义的 PHT 和 HBV 相关 HCC 且肿瘤符合米兰标准的患者中开展的开放性随机临床试验。这些患者于 2012 年 12 月至 2018 年 6 月按 1:1 随机分配至部分肝切除术组或介入治疗组。主要终点为总生存期(OS);次要终点包括无复发生存期(RFS)和治疗安全性。

结果

每组各 80 例患者。部分肝切除术组和介入治疗组的 1 年、3 年和 5 年 OS 率分别为 95.0%、86.2%、69.5%和 93.8%、77.5%、64.9%(P=0.325)。相应的 RFS 率分别为 78.8%、55.0%、46.2%和 71.3%、52.5%、45.0%(P=0.783)。与介入治疗组相比,部分肝切除术组的并发症发生率更高(67.5% vs. 20%,P<0.001),但主要为 Clavien-Dindo Ⅰ级并发症(P<0.001),而Ⅱ/Ⅲ/Ⅳ/Ⅴ级并发症无显著差异(均 P>0.05)。

结论

本研究表明,对于米兰标准范围内、伴有临床显著 PHT 的 HBV 相关 HCC 患者,与介入治疗相比,部分肝切除术在 OS 和 RFS 方面未达到预设的显著改善。然而,部分肝切除术仍是一种安全的治疗方法,应被视为一种治疗选择,而非禁忌证。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c0a/11570767/19316b96c56f/CAC2-44-1337-g002.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验